The role of vascular growth factors in diabetic retinopathy and macular edema development

Iskhakova, A.G.; Золотарев, А. В.; Viktorov, D. A.; Toropovsky, A.N.; Nikitin, Alexey

doi:10.21516/2072-0076-2018-11-2-62-69

Cited by 2 publications

(1 citation statement)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Действие VEGF опосредуется через тирозинкиназные рецепторы I и II типа -VEGFR-1 и VEGFR-2, присутствующие на поверхности эндотелиальных клеток [4]. Гиперсекреция VEGF приводит к двум основным биологическим эффектам: повышению проницаемости собственных сосудов и стимуляции роста новообразованных [5]. В связи с этим терапия ДМО препаратами -ингибиторами VEGF представляется патогенетически обоснованной.…”

Section: в помощь практическому врачуunclassified

Experiences of using Aflibercept in diabetic macular edema treatment: data from routine clinical practice

Santoro

2018

Rossijskij oftalʹmologičeskij žurnal

View full text Add to dashboard Cite

Purpose. To assess the effectiveness and safety of intravitreal aflibercept injections in clinically significant diabetic macular edema (DME) in a routine clinical practice.Material and methods. This was a prospective, observational, single-center study. During the study, anti-VEGF treatment naïve patients with clinically significant DME received five monthly intravitreal injections of aflibercept 2 mg followed by bimonthly injections. The observation period was 1 year.Results. The study included 11 eyes of 10 patients with clinically significant DME. Use of 8 intravitreal aflibercept injections resulted in central retinal thickness (CRT) reduction by 50 % from the baseline within 1 year of therapy. CRT decreased on average from 446.18 ± 106.88 μm to 226.27 ± 44.56 μm by the end of observational period. In addition, an increase in visual acuity was observed from an average from 0.33 ± 0.22 at the start of therapy to 0.62 ± 0.33 at the end of the observation. Serious adverse events over the entire period of treatment were not observed.Conclusion. Aflibercept showed high efficacy and safety in the treatment of clinically significant DME in routine clinical practice. To obtain optimal functional and morphological results in the treatment of patients with DME, it is necessary to start therapy with 5 loading intravitreal aflibercept injections.

show abstract

Section: в помощь практическому врачуunclassified

Experiences of using Aflibercept in diabetic macular edema treatment: data from routine clinical practice

Santoro

2018

Rossijskij oftalʹmologičeskij žurnal

View full text Add to dashboard Cite

show abstract

Nitrogen and oxygen levels in placenta - a predictor for retinopathy of prematurity

Deev

Nivenitsyn

et al. 2019

Vestn. oftal'mol.

View full text Add to dashboard Cite

The role of vascular growth factors in diabetic retinopathy and macular edema development

Cited by 2 publications

References 32 publications

Experiences of using Aflibercept in diabetic macular edema treatment: data from routine clinical practice

Experiences of using Aflibercept in diabetic macular edema treatment: data from routine clinical practice

Nitrogen and oxygen levels in placenta - a predictor for retinopathy of prematurity

Contact Info

Product

Resources

About